Second-generation tyrosine kinase inhibi
β
Ayalew Tefferi
π
Article
π
2010
π
John Wiley and Sons
π
English
β 86 KB
Imatinib should continue to be the frontβline therapy for patients who have newly diagnosed chronic myelogenous leukemia accompanied by close monitoring. Patients should switch to a secondβgeneration tyrosine kinase inhibitor at the earliest sign of resistance or suboptimal response to imatinib.